JPMorgan Chase & Co’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-697,510
| Closed | -$28.5M | – | 6610 |
|
|
2024
Q2 | $28.5M | Buy |
697,510
+257,344
| +58% | +$10.5M | ﹤0.01% | 1431 |
|
|
2024
Q1 | $18.6M | Buy |
440,166
+283,358
| +181% | +$12M | ﹤0.01% | 1727 |
|
|
2023
Q4 | $6.65M | Buy |
156,808
+59,523
| +61% | +$2.52M | ﹤0.01% | 2377 |
|
|
2023
Q3 | $2.12M | Sell |
97,285
-64,066
| -40% | -$1.4M | ﹤0.01% | 2960 |
|
|
2023
Q2 | $5.13M | Sell |
161,351
-1,343
| -0.8% | -$42.7K | ﹤0.01% | 2474 |
|
|
2023
Q1 | $3.97M | Buy |
162,694
+31,722
| +24% | +$774K | ﹤0.01% | 2592 |
|
|
2022
Q4 | $4.13M | Buy |
130,972
+498
| +0.4% | +$15.7K | ﹤0.01% | 2515 |
|
|
2022
Q3 | $3.69M | Buy |
130,474
+71,361
| +121% | +$2.02M | ﹤0.01% | 2536 |
|
|
2022
Q2 | $1.56M | Buy |
59,113
+10,907
| +23% | +$288K | ﹤0.01% | 3168 |
|
|
2022
Q1 | $1.69M | Buy |
48,206
+5,467
| +13% | +$191K | ﹤0.01% | 3289 |
|
|
2021
Q4 | $1.39M | Buy |
42,739
+13,345
| +45% | +$432K | ﹤0.01% | 3471 |
|
|
2021
Q3 | $868K | Buy |
29,394
+5,595
| +24% | +$165K | ﹤0.01% | 3692 |
|
|
2021
Q2 | $610K | Buy |
23,799
+21,164
| +803% | +$542K | ﹤0.01% | 3886 |
|
|
2021
Q1 | $36K | Buy |
+2,635
| New | +$36K | ﹤0.01% | 4866 |
|